dalteparin has been researched along with Placental Abruption in 6 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Rottenstreich, A | 1 |
| Gershgoren, H | 1 |
| Spectre, G | 1 |
| Da'as, N | 1 |
| Bentur, OS | 1 |
| Levin, G | 1 |
| Kalish, Y | 1 |
| Haddad, B | 2 |
| Winer, N | 1 |
| Chitrit, Y | 1 |
| Houfflin-Debarge, V | 1 |
| Chauleur, C | 2 |
| Bages, K | 1 |
| Tsatsaris, V | 1 |
| Benachi, A | 1 |
| Bretelle, F | 1 |
| Gris, JC | 2 |
| Bastuji-Garin, S | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Faillie, JL | 1 |
| Baer, G | 1 |
| Marès, P | 1 |
| Fabbro-Peray, P | 1 |
| Quéré, I | 1 |
| Lefrant, JY | 1 |
| Dauzat, M | 1 |
| Santoro, R | 1 |
| Iannaccaro, P | 1 |
| Sottilotta, G | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Rey, E | 1 |
| David, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial[NCT00986765] | Phase 3 | 257 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dalteparin and Placental Abruption
| Article | Year |
|---|---|
Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
Topics: Abruptio Placentae; Adult; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Humans; Pre-Eclam | 2016 |
Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial.
Topics: Abruptio Placentae; Adult; Enoxaparin; Female; Humans; Pilot Projects; Pregnancy; Pregnancy Complica | 2010 |
4 other studies available for dalteparin and Placental Abruption
| Article | Year |
|---|---|
Factors associated with pregnancy outcomes in women with a history of cerebral sinus venous thrombosis.
Topics: Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Case-Control Studies; Enoxaparin; | 2020 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
Congenital hypodysfibrinogenemia and abruptio placentae in a woman with history of cerebral thrombosis.
Topics: Abruptio Placentae; Adult; Anticoagulants; Enoxaparin; Female; Fibrinogens, Abnormal; Heparin; Human | 2007 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |